P690 Changes of intestinal microbiota in patients with inflammatory bowel diseases
Baryshnikova, N.(1);Uspenskiy, Y.(1);Suvorova, M.(2);Lyudyno , V.(2);Suvorov, A.(3);
(1)Pavlov First St-Petersburg State medical university, internal diseases, St-Petersburg, Russian Federation;(2)Institute of experimental medicine, diagnostic laboratory, St-Petereburg, Russian Federation;(3)Institute of experimental medicine, molecular microbiology department, St-Petereburg, Russian Federation
Background
Normal microbiota is one of the main topic controling normal function of human organism. Microbiota changes and dysbiosis are the important factors in the pathogenesis of different digestive diseases, including inflammatory bowel diseases (IBD). The aim: estimation the intestinal microbiota changes in patients with IBD.
Methods
We investigated fecal samples to determine features of intestinal microbiota in 17 patients with IBD in acute phase of diseases: 10 patients with ulcerative colitis and 7 patient with Crohn's disease, four patients received therapy with immunodiological agents. For feces analysis we used real-time polymerase chain reaction with fluorescent detection. Statistical processing was performed using the SPSS8.0 software package.
Results
100% of patients showed some changes in gut microbiota. These disorders were different in patients but no any significant changes in ulcerative colitis and Crohn's disease patients. We saw the most frequent and significant changes:
1. decrease of Lactobacillus spp. level was determined in 59% of those examined
2. increase of Bifidobacterium spp. level was determined in 47% of patients
3. changing of the ratio of Bacteroides spp./Faecalibacterium prausnitzii towards increase of Bacteroides - in 24% of patients
4. frequency of occurrence of C. difficile was 24% of patients
5. frequency of occurrence of Candida spp. was in 35% of patients.
In a number of patients, increased growth of opportunistic bacteria was detected: Proteus vulgaris/mirabilis - 24%, Citrobacter spp. - 29%, Enterobacter spp. - 12%.
Microboal indirect microbial markers of colon oncopathology Fusobacterium nucleatum was identified in 18% and Parvimonas micra - in 24%. F. nucleatum and P. micra have higher frequency in patient who received immimmunodiological agents.
Conclusion
Patients with IBD show a downward trend in Lactobacillus spp. and increasing Bifidobacterium spp., whereby lacto-containing probiotics may be recommended for such patients and Bifidobacteria-containing probiotic may be not recommended. There is also a relatively high incidence of F. nucleatum and P. micra in IBD patients, which dictates the need for dispensary surveillance of these patients not only for the purpose of controlling the onset and maintenance of remission, but also for the purpose of early detection of colorectal cancer and IBD-associated malignancies.